AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...

AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer patients. The system, which was already FDA-cleared for the surgical ...

The clearance for the NanoKnife System for prostate tissue ... ablating prostate tissue in patients with intermediate-risk prostate cancer (PCa). The latest regulatory clearance is a significant ...

George was the youngest person to be treated for cancer with Nanoknife technology - also known as irreversible ...

AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target and destroy tissue without delivering excess heat and the unintended ...

"The NanoKnife System minimizes the life-altering ... of the NanoKnife System in patients with immediate-risk prostate cancer. The results reinforced findings from more than 32 other studies ...

A study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk ...

Screening men born with a high risk of developing prostate cancer, once they reach the age of 45, makes financial sense, a cancer charity says. But Prostate Cancer Research also acknowledges more ...

Dr Paul Cornes is calling for more information about the new trial A new trial to cut prostate cancer deaths may harm patients as many will still go through aggressive treatment "unnecessarily", a ...

Attendees will gain insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men ...